Clinical Trials
43 trialsAPOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
National Cancer Institute (NCI)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
National Institutes of Health Clinical Center (CC)
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
National Institutes of Health Clinical Center (CC)
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
National Institutes of Health Clinical Center (CC)
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
National Cancer Institute (NCI)
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
National Cancer Institute (NCI)
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
National Cancer Institute (NCI)
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Genomic Services Research Program
National Institutes of Health Clinical Center (CC)
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
National Institutes of Health Clinical Center (CC)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
Men at High Genetic Risk for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Institutes of Health Clinical Center (CC)
Collection of Blood From Patients With Cancer
National Institutes of Health Clinical Center (CC)
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Institutes of Health Clinical Center (CC)
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Institutes of Health Clinical Center (CC)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)